Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

212

Webcast: Access available at http://www.curagen.com

A replay of the conference call will be available starting at 2:00 p.m. Eastern time on Monday, November 3, 2008 through Wednesday, December 3, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 71190212. An archive of the webcast will be available for 30 days at http://www.curagen.com.

About CR011-vcMMAE

CR011-vcMMAE is an antibody-drug conjugate (ADC) being developed by CuraGen that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics, Inc. (Nasdaq: SGEN). The ADC is designed to be stable in the bloodstream. Following intravenous administration, CR011-vcMMAE targets and binds to GPNMB, a specific protein that is predominantly expressed on the surface of cancer cells, including melanoma, breast cancer and gliomas. Upon internalization into the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. CR011-vcMMAE is currently in two Phase II trials assessing the safety and efficacy in the treatment of melanoma and for the treatment of metastatic breast cancer, and in a Phase I trial to evaluate the safety and activity of alternate dosing schedules.

About Melanoma

According to the American Cancer Society, it is expected that approximately 60,000 new cases of melanoma will be diagnosed, including nearly 11,000 patients diagnosed with Stage III or Stage IV disea
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Call/ -- Medco Health Solutions, Inc (NYSE: MHS ...rican healthcare through an advanced, wired pharma...ity clinical care and fundamentally bending the co...he benefit of patients and payors alike. ,, The...trategy enable "Smarter Medicine" to help address ...
(Date:11/20/2009)...-- ,, Reportlinker.com announces that a new ma.... ,, India Medical Equipment Market Analysis a...ker.com/p0164658/India-Medical-Equipment-Market-An...swire&utm_medium=pr&utm_campaign=prnewswir...ent Market Analysis and Forecasts to 2015 ,, S...
(Date:11/20/2009)...tCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) a...mber 30, 2009 with net earnings of $128,000, or $0... This compares to net earnings of $328,000, or $0....r the first quarter of last year. ,, Commenting...d CEO Steve Springrose said: "Biotel enjoyed stron...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Biotel Announced Profitable First Quarter Ended September 30, 2009 2Healthcare Reform Starts at Home 52243 1Healthcare Reform Starts at Home 52243 2Healthcare Reform Starts at Home 52243 3Healthcare Reform Starts at Home 52243 4Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced 4761 1Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced 4761 2Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced 4761 3Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced 4761 4Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced 4761 5Avidas 28TM 29 Pharmaceuticals and LaRon 28TM 29 Pharma Inc Announce Co Promotion Agreement 52241 1Avidas 28TM 29 Pharmaceuticals and LaRon 28TM 29 Pharma Inc Announce Co Promotion Agreement 52241 2Avidas 28TM 29 Pharmaceuticals and LaRon 28TM 29 Pharma Inc Announce Co Promotion Agreement 52241 3Avidas 28TM 29 Pharmaceuticals and LaRon 28TM 29 Pharma Inc Announce Co Promotion Agreement 52241 4
... In,conjunction with QIAGEN,s Third Quarter 2007 E...conference call which will be broadcast live over,...a.m. EST, with Peer M.,Schatz, President and Chief...cial Officer. What: QIAGEN N.V. -- Third Quar..., November 6, 2007 at 9:30 a.m. EST, Where: h...
...ng researchers,will present 68 data presentations ...cluding PEGINTRON(TM) (peginterferon alfa-2b) and ... current standard of care in the,treatment of chro...for the,Study of Liver Diseases (AASLD) Annual Mee... studies discussing the predictability of,response...
Other Medicine Technology:QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web 2Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting 7
(Date:11/21/2009)...oup merges their practice with that of E. Steven P... (PRWEB) November 21, 2009 -- The New Haven...son, Dr. Dean Cloutier, Dr. John Plachtyna and Dr....actice with that of esteemed colleague Dr. E. Stev... to retire from dentistry in order to concentrate ...
(Date:11/20/2009)...nderstanding Brain Wiring and Diseases ,, WASHI...my Schmahmann, Professor of Neurology at Harvard M... General Hospital in Boston, on Thursday, November...w field of study called "Connectivity" at the laun...n is an award-winning leader in the field of the c...
(Date:11/20/2009)...USNewswire/ -- The American Academy of Actuarie ... legislation released this week to contain stronge... coverage mandate. The actuaries said that an effe...e selection stemming from more restrictive issue a... individual mandate language should be strengthene...
(Date:11/20/2009).../ -- Following a recall by Unilever The Stop &...s Country Crock ® Side Dishes DELUXE Cheddar ...e Dishes DELUXE Four Cheese Pasta due to an undecl...ates and UPCs are affected: ,, Shedd,s Country...Rice 21 oz, UPC 027400218316, Best By NOV 29 09 th...
(Date:11/20/2009)...ire-FirstCall/ -- Rates of infection by the 2009 H...r, but the pandemic flu virus continues to be a po...ding the elderly, according to a new report by Que...rld,s leading provider of diagnostic testing, info...est Diagnostics Health Trends(TM) Report "Testing ...
Breaking Medicine News(10 mins):Health News:New Haven Dental Group Expands Their Vision 2Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...oes not increase the chances of heart attack, but ... movie mythology. //The study reported that ‘while...tack, use of cocaine could lift the likelihood 20-...caine use, pollution, heavy meals, and stressful e...
...rted on Monday that millions of newborn babies, //...preventable diseases in spite of promises of bette... The WHO reported that because of AIDS and armed...African countries accounted for 19 of the 20 count...
...risk of dementia according to recent research. // ... a lower risk of dementia and Alzheimer’s disease....ish oil is a key factor that is required for the p...o lead researcher Dr. Ernst J. Schaefer, director ...
...rs at seven district health boards (DHBs) who ten ...h their dispute over pay parity still unresolved. ...tingency planning for the DHBs, said that she expe... we will be back to normal." However, she said...
...S cases reported from strife-torn Afghanistan, hav...The increasing use of heroin has raised concern am... abetting the spread of AIDS in the nation. ...ty to 50 percent of refugees use heroin and 20 to ...
...rgy to grass pollen will now benefit from a suitab...t based //vaccine named Grazax? is being marketed ...n allergy treatment. Allergy from grass pollen ...illion Europeans suffer from this allergy which le...
Other Medicine News:Health News:WHO Attributes Death of Millions in Africa to Treatable diseases 2Health News:Radiographers Pay Parity Disputes Still Unresolved 2
Reddick/Saye Needle Holder, Curved Right
MultAcoice™ Grasping Forceps 2x3 Teeth
ROTICULATOR ENDO GRASP™ 5 mm Instrument With Spin Lock
...order products are offered as 1-piece or modular, ...ruments may be customized with handles of choice a...flush ports. Many standard patterns are available ...ffect delivery times. , Please Note: Individual ...
Medicine Products: